Immunology and Infectious Diseases

Novartis has a diverse portfolio of medications to treat disorders that affect the body’s immune response and occur when the immune system is overactive and/or begins to fight against itself.
In Immunology and Infectious Diseases, our focus is on the following disease areas:*

Transplantation
We have a broad portfolio of immunosuppressants which are used to help prevent organ rejection. These include Neoral (cyclosporine), Simulect (basiliximab), myfortic (micophenolic acid) and Certican/Zortress (everolimus).

We are also developing new medications for patients requiring a kidney, liver or heart transplantation.

Nephrology / Hepatitis
Our portfolio includes Tyzeka/Sebivo(telbivudine), a therapy for chronic hepatitis B, as well as development projects addressing hepatitis C and chronic kidney disease.

Autoinflammatory and autoimmune diseases
Ilaris (canakinumab) is a new biological medicine that treats a rare autoinflammatory disease with debilitating symptoms called cryopyrin-associated periodic syndromes (CAPS).

We are also developing new treatments for patients suffering from chronic autoimmune diseases such as psoriasis, rheumatoid arthritis and gouty arthritis.

Additional marketed products include Aclasta/Reclast (zoledronic acid 5 mg), a once-yearly infusion to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, and Cubicin (daptomicyn), an antibiotic for severe infections. Development of new treatments for complicated infections caused by multiresistant microbes and bacteria is ongoing.

 

*Not all indications are available in all countries.